Blood-pressure-related disease is a global health priority.

Distribution and determinants of non communicable diseases among elderly Uyghur ethnic group in Xinjiang, China. PLoS One (2014) 0.84

Burden and correlates of non-communicable-diseases among rural residents: a cross-sectional study in Hebei, China. BMC Public Health (2015) 0.76

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18

Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43

Severe hypoglycemia and risks of vascular events and death. N Engl J Med (2010) 8.54

Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA (2005) 6.68

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 6.26

Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet (2014) 6.23

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03

Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19

Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med (2014) 4.88

Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet (2007) 4.74

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med (2007) 3.74

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA (2002) 3.70

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA (2004) 3.68

Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med (2005) 3.44

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42

Systolic pressure is all that matters. Lancet (2008) 3.42

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol (2005) 3.27

Sodium intake and mortality in the NHANES II follow-up study. Am J Med (2006) 3.24

Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA (2005) 3.19

Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens (2006) 3.12

Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.10

Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA (2007) 3.09

Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med (2003) 3.02

Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation (2005) 2.97

The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96

Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) (2013) 2.94

Hypertension in sub-Saharan African populations. Circulation (2005) 2.91

Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens (2014) 2.82

Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation (2010) 2.74

World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens (2007) 2.71

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 2.69

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64

Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64

Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J Hypertens (2010) 2.49

Blood pressure and the global burden of disease 2000. Part 1: estimates of blood pressure levels. J Hypertens (2006) 2.43

The burden of blood pressure-related disease: a neglected priority for global health. Hypertension (2007) 2.30

In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension (2007) 2.27

Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation (2011) 2.17

Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med (2003) 2.09

Hypertension control in community health centers across China: analysis of antihypertensive drug treatment patterns. Am J Hypertens (2013) 2.08

Global inequalities in access to cardiovascular health care: our greatest challenge. J Am Coll Cardiol (2008) 2.06

Common genetic variants of the human uromodulin gene regulate transcription and predict plasma uric acid levels. Kidney Int (2013) 2.05

Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol (2005) 2.05

ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02

Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA (2006) 2.00

Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction. Circulation (2009) 1.99

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care (2009) 1.89

High remaining risk in poorly treated hypertension: the 'rule of halves' still exists. J Hypertens (2002) 1.89

Sodium intake and mortality follow-up in the Third National Health and Nutrition Examination Survey (NHANES III). J Gen Intern Med (2008) 1.79

Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension (2010) 1.74

Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2006) 1.73

Hypertension and health-related quality of life: an epidemiological study in patients attending hospital clinics in China. J Hypertens (2005) 1.72

Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial. BMJ (2006) 1.71

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens (2006) 1.71

A call for higher standards of evidence for dietary guidelines. Am J Prev Med (2008) 1.69

Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol (2009) 1.68

Effect of physician volume on the relationship between hospital volume and mortality during primary angioplasty. J Am Coll Cardiol (2009) 1.67

Acute myocardial infarction hospitalization in the United States, 1979 to 2005. Am J Med (2010) 1.63

The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J (2009) 1.60

Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels. Am J Hypertens (2013) 1.57

Hypertension prevalence, awareness, treatment, and control in 115 rural and urban communities involving 47 000 people from China. J Hypertens (2016) 1.57

Hypertension control at physicians' offices in the United States. Am J Hypertens (2008) 1.56

Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circ Arrhythm Electrophysiol (2008) 1.56

Renal dysfunction and ischemic heart disease mortality in a hypertensive population. J Hypertens (2005) 1.55

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens (2004) 1.53

Is high pulse pressure a marker of preclinical cardiovascular disease? Hypertension (2005) 1.53

Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension (2004) 1.52

The association between changes in urinary albumin-to-creatinine ratio and risk of abnormal ankle-brachial index in a community-based Chinese population. J Atheroscler Thromb (2012) 1.51

The rising burden of diabetes and hypertension in southeast asian and african regions: need for effective strategies for prevention and control in primary health care settings. Int J Hypertens (2013) 1.50

Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction. Am Heart J (2004) 1.50

Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension (2005) 1.49

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens (2009) 1.48

A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev (2013) 1.47

Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease. Eur Heart J (2005) 1.46

Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings. J Clin Epidemiol (2011) 1.46

Verbal autopsy coding: are multiple coders better than one? Bull World Health Organ (2009) 1.45

Prediabetes and short-term outcomes in nondiabetic patients after acute ST-elevation myocardial infarction. Cardiology (2013) 1.44

Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke (2009) 1.43

Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study. J Hypertens (2002) 1.43

Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. Am J Hypertens (2010) 1.42

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation (2007) 1.41

The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens (2011) 1.41

Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease. Eur Heart J (2002) 1.40

Incidence of heterotopic bone formation after major hip surgery. ANZ J Surg (2002) 1.38

The occurrence of leg ulcers in Auckland: results of a population-based study. N Z Med J (2002) 1.38

The common rs9939609 variant of the fat mass and obesity-associated gene is associated with obesity risk in children and adolescents of Beijing, China. BMC Med Genet (2010) 1.31

Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation (2014) 1.30

Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens (2011) 1.27

Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history. Stroke (2009) 1.27

Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J (2011) 1.23